Are Utah pharmacists exempt from strict products liability? Schaerrer v. Stewart's Plaza Pharmacy Explained

In Schaerrer v. Stewart’s Plaza Pharmacy, the Utah Supreme Court addressed whether pharmacists can be held strictly liable for prescription drugs they compound and dispense. The court’s decision significantly clarifies the scope of strict products liability for Utah pharmacies.

Background and Facts

Plaintiff Jeanne Schaerrer suffered heart valve damage after taking fenfluramine and phentermine for weight loss. Stewart’s Plaza Pharmacy had compounded a “one-a-day fen-phen” capsule combining fenfluramine, phentermine, a time-release agent, and filler. The pharmacist created samples for local physicians and received prescriptions for the compounded product. Schaerrer sued Stewart’s under strict products liability theory, arguing the pharmacy acted as a manufacturer rather than a traditional pharmacist.

Key Legal Issues

The central question was whether Stewart’s conduct transcended pharmaceutical practice and constituted drug manufacturing, thereby subjecting it to strict liability. The court also considered whether the learned intermediary rule should extend to pharmacists, exempting them from strict liability for failure to warn patients directly about prescription drug risks.

Court’s Analysis and Holding

The Utah Supreme Court held that pharmacists are exempt from strict products liability under the learned intermediary rule when properly filling physician prescriptions. The court adopted the principle that physicians act as “exclusive intermediaries” in the drug distribution system, making them best positioned to weigh risks and benefits for individual patients. Requiring pharmacists to warn patients directly would “undermine the physician-patient relationship by engendering fear, doubt, and second-guessing.”

Examining Stewart’s specific conduct, the court found the pharmacy’s activities fell within legitimate pharmaceutical practice under Utah statutes. While the court acknowledged some concern about distributing sample capsules to physicians, it distinguished between small-scale compounding and large-scale manufacturing. The court noted no evidence of wholesale distribution, commercial-scale equipment, or violation of state and federal regulations governing pharmacy practice.

Practice Implications

This decision provides important protection for Utah pharmacists engaged in traditional compounding activities. However, pharmacists remain subject to negligence claims for professional malpractice. The court emphasized that crossing into manufacturing requires evidence of large-scale compounding, third-party resale, wholesale distribution, or other indicators of non-traditional pharmaceutical behavior. Utah practitioners should carefully evaluate whether a pharmacy’s conduct falls within accepted pharmaceutical practice when analyzing potential liability theories.